Atrium divests chemicals division
This article was originally published in The Tan Sheet
Executive Summary
Health and nutrition product marketer Atrium has completed the sale of its active ingredients and specialty chemicals division to Unipex Group for $166.4 million in cash, "subject to post-closing working capital adjustment," the company announces May 22. Proceeds will provide the firm better financial flexibility to pursue its corporate strategy, the Quebec City, Canada-based company notes. With the sale, Atrium has reached its goal of focusing entirely on health and nutrition products (1"The Tan Sheet" Jan. 6, 2008, In Brief)...
You may also be interested in...
Atrium re-evaluates business
In an effort to better position itself as a leader in the health and nutritional products arena, Atrium Innovations is considering a sale of its active ingredients and specialty chemicals division, the Canadian nutritional products marketer announces Dec. 18. A sale of the division would "strengthen Atrium with a targeted vision and development strategy in the high potential nutritional supplements market," the Quebec-based firm says, noting it plans to act as a consolidator in the fragmented segment. Atrium strengthened its health division with the purchase of German-based Mucos in July and was recently granted permission to sell Mucos' enzyme-based supplement Wobenzym N in the U.S. (1"The Tan Sheet" Nov. 26, 2007, In Brief)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.